N/A N=61 Endothelial Dysfunction in Obese Children
Obesity · Atherosclerosis
Primary: Change From Baseline in Reactive Hyperemia Index at 5 and 10 Months — 1.9; 1.5; 2.01; 1.55 arbitrary units — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=102 Periodontal Infection and Endothelial Dysfunction
Periodontitis
Primary: Brachial Artery Flow-mediated Dilation — 10.2; 10.3; 13.1; 8.1 Percentage of dilatation of brachial art — p=0.98
Phase 1 N=19 Effect of Vitamin D Supplementation on Endothelial Function in Obese Adolescents
Obesity · Endothelial Dysfunction · Vitamin D Deficiency
Primary: Flow Mediated Dilatation (FMD) — 9.5; 10.4 percentage increase in BAD — p=0.59
N/A N=20 Sex Differences in Vascular Responses to Exercise
Aging
Primary: Change in FMD in Response to Chronic HIIT — 0.11; 0.57; 0.81; 0.10 % flow mediated dilation
Phase 2 N=15 Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change in Flow Mediated Dilation — 0.26; -1.5 percentage of flow mediated dilation
Early Phase 1 N=30 Contribution of Endothelin-1 to Exercise Intolerance in Heart Failure
Heart Failure
Primary: Blood Flow — 300; 275 ml/min
Phase 2 N=94 Inflammation and Coronary Endothelial Function
Coronary Artery Disease
Primary: Percent Change in Coronary Cross Sectional Area (CSA) From Rest to That During Isometric Handgrip Exercise (IHE) — -1.70; 2.71; -0.39; 2.04 Percent change from rest…
N/A N=89 Comparing Blood Vessel Endothelial Function in HIV-Infected People and Matched HIV-Uninfected People
HIV Infection
Primary: Endothelial Function (Brachial Artery Reactivity) — 3.98; 3.37 percent dilation — p=0.10
N/A N=14 Vascular Dysfunction During Physical Inactivity
Aging · Vascular Endothelium · Skeletal Muscle
Primary: Brachial Artery Vascular Function — 5.1; 3.1; 4.4 percent vasodilation
Phase 2 N=64 Cystic Fibrosis and Endothelial Function: At Rest and During Exercise
Cystic Fibrosis
Primary: Percentage Flow-Mediated Dilation (FMD) — 5.64; 5.32; 6.29; 7.21 percentage of change in FMD
N/A N=13 FFA-Induced Hypertension and Endothelial Dysfunction
Endothelial Dysfunction · Hypertension
Primary: Change in Systolic Blood Pressure to After Completing an 8-hour Normal Saline Infusion in Obese Normotensive Subjects. — 13 mmHg
N/A N=45 Dyslipidemia and Diabetic Retinopathy
Diabetic Retinopathy · Dyslipidemia
Primary: Increase in Acid Sphingomyelinase (ASM) Expression and Activity in Bone Marrow-derived Endothelial Progenitor Cells (EPCs) — 0.2; 0.5 nM/hr
Phase 2 N=26 CD36 in Nutrient Delivery and Its Dysfunction
Insulin Resistance · Endothelial Dysfunction
Primary: Change in Microvascular Blood Volume (MBV) During Insulin Infusion — 13.16; 11.3 ml/kg
N/A N=60 Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Flow-Mediated Dilation (FMD) — 3.1; 6.7; 4.7; 6.9 percentage of change in FMD — p=<0.05
N/A N=47 Influence of Endothelial Function on Central and Peripheral Causes Of Exercise Impairment in Type 2 Diabetes
Type 2 Diabetes
Primary: Percent Change in Circumferential Strain Before and After Exercise at Baseline, After Vitamin C Infusion, and After Exercise Training — -24; -20; -23; -21 percentage of…
Phase 2 N=23 Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI
Myocardial Reperfusion Injury
Primary: Average Peak Velocity (APV) Immediately Following Percutaneous Coronary Intervention (PCI) — 30; 19 cm/s — p=0.029
Phase 2 N=14 Role of Neuraminidase Activity on Endothelial Dysfunction in Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change in Glycocalyx Integrity-Perfused Boundary Region — -0.0057 micrometers (mcm)
N/A N=35 Hyperglycemia and Mitochondrial Function in The Endothelium of Humans
Diabetes · Hyperglycemia
Primary: Change in Mitochondrial Network Complexity of Endothelial Cells as Measured by Mitochondrial Network Fragment Ratio
N/A N=70 Mechanisms of Endothelial Cell Dysfunction in Sleep Apnea
Obstructive Sleep Apnea · Hypoxemia
Primary: ODI — 24.71; .97 events/hour
N/A N=80 Uric Acid and the Endothelium in CKD
Kidney Disease
Primary: Change in Endothelial Dependent Dilation From Baseline to Week 12 — 0.2; 0.9 % change — p=0.47
Phase 2 N=9 Vitamin D to Improve Endothelial Function in SLE
Atherosclerosis · Systemic Lupus Erythematosus
Primary: Change at Week 16 in % Flow Mediated Dilation in Those Who Did and Did Not Replete Vitamin D — 1.4; -4.2 Absolute change in % FMD — p=> 0.05
N/A N=27 Effect of Dietary Sodium Intake on Vascular Endothelium
Postural Tachycardia Syndrome (POTS)
Primary: FMD (% Change) — 12.75; 11.65; 11.43; 12.75 percentage of change
Phase 3 N=24 Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular Adaptations in Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Glygocalyx Integrity - Perfused Boundary Region — 0.11; -0.16 Delta micrometers (mcm)
N/A N=19 Endothelial Function in Lower Extremity Bypass Grafts
Peripheral Arterial Disease
Primary: Change From Baseline in Saphenous Vein Bypass Graft Vasodilation — 5.28 vein bypass graft size increase (%)
N/A N=20 Vascular Endothelium Changes After Bariatric Surgery (Endothelial Progenitor Cells)
Type 2 Diabetes
Primary: Change in Late Outgrowth Endothelial Progenitor Colonies — 0.3; 0.2; 3.1; 0.1 LOEPC colonies — p=<0.05
N/A N=88 HIV-1, Insufficient Sleep and Vascular Endothelial Dysfunction
HIV-1
Primary: Phase 1: Forearm Blood Flow (FBF) Response to Acetylcholine (ACh) — 4.6; 4.2; 11.7; 9.9 mL/100 mL tissue/min
N/A N=20 Cardioprotective Activities Of Whole Eggs On Vascular Endothelial Function In Prediabetic Adults
Prediabetes · Cardiovascular Disease
Primary: Vascular Endothelial Function — -294.4; -152.9; -102.9; -361.6 %FMD*min
Phase 2 N=70 Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial
Chronic Kidney Disease
Primary: Mean Percentage Change in Endothelium-dependent Flow-mediated Vasodilation (FMD) Over 12 Weeks — 1.1; 0.3 Percentage change
Phase 2 N=34 Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction
Metabolic Syndrome · Coronary Microvascular Dysfunction
Primary: Absolute Change in Coronary Cross-sectional Area (in mm²) Within the Vericiguat Group as Assessed by Magnetic Resonance Imaging (MRI) — -1.11; 0.40 mm^2 — p=0.0005
Phase 2 N=36 Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells
Diabetes Mellitus · Metabolic Syndrome X · Hypercholesterolemia
Primary: Change in Plasma Thiobarbituric Acid Reactive Substance (TBARS) Levels — 2.1; 2.5 nmol/mL